Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $37.25.
Several equities research analysts recently issued reports on ZLAB shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research note on Tuesday, October 6th. Wall Street Zen upgraded Zai Lab from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. Citigroup raised their price objective on shares of Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a research report on Tuesday, October 27th.
Read Our Latest Analysis on ZLAB
Zai Lab Price Performance
NASDAQ:ZLAB opened at $23.47 on Thursday. The firm has a market cap of $2.94 billion, a PE ratio of -13.11 and a beta of 0.77. The firm has a 50 day simple moving average of $24.56 and a 200-day simple moving average of $21.29. Zai Lab has a 1-year low of $15.96 and a 1-year high of $29.02.
Zai Lab (NASDAQ:ZLAB – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18. The firm had revenue of $108.21 million during the quarter, compared to the consensus estimate of $107.90 million. Zai Lab had a negative net margin of 44.91% and a negative return on equity of 31.15%. As a group, sell-side analysts expect that Zai Lab will post -2.19 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Zai Lab news, Director Richard Gaynor purchased 1,228 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The stock was bought at an average price of $27.19 per share, with a total value of $33,389.32. Following the completion of the purchase, the director owned 81,965 shares in the company, valued at $2,228,628.35. This trade represents a 1.52% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.88% of the stock is owned by insiders.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Headlands Technologies LLC lifted its position in Zai Lab by 142.0% in the 2nd quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock worth $1,292,000 after buying an additional 39,901 shares in the last quarter. Seven Fleet Capital Management LP grew its holdings in Zai Lab by 74.7% during the second quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company’s stock valued at $2,584,000 after purchasing an additional 58,158 shares during the last quarter. WealthPlan Investment Management LLC acquired a new position in Zai Lab during the third quarter valued at approximately $969,000. Nan Fung Trinity HK Ltd. raised its position in shares of Zai Lab by 106.9% in the third quarter. Nan Fung Trinity HK Ltd. now owns 293,966 shares of the company’s stock valued at $7,743,000 after purchasing an additional 151,883 shares during the period. Finally, Alps Advisors Inc. boosted its stake in Zai Lab by 34.9% during the 3rd quarter. Alps Advisors Inc. now owns 148,993 shares of the company’s stock valued at $3,924,000 after purchasing an additional 38,562 shares during the period. Institutional investors own 41.65% of the company’s stock.
Zai Lab Company Profile
Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.
See Also
- Five stocks we like better than Zai Lab
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.
